1
|
Malhaire C, Selhane F, Saint-Martin MJ, Cockenpot V, Akl P, Laas E, Bellesoeur A, Ala Eddine C, Bereby-Kahane M, Manceau J, Sebbag-Sfez D, Pierga JY, Reyal F, Vincent-Salomon A, Brisse H, Frouin F. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy. Eur Radiol 2023; 33:8142-8154. [PMID: 37318605 DOI: 10.1007/s00330-023-09797-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 04/14/2023] [Accepted: 05/13/2023] [Indexed: 06/16/2023]
Abstract
OBJECTIVES To evaluate the association between pretreatment MRI descriptors and breast cancer (BC) pathological complete response (pCR) to neoadjuvant chemotherapy (NAC). MATERIALS AND METHODS Patients with BC treated by NAC with a breast MRI between 2016 and 2020 were included in this retrospective observational single-center study. MR studies were described using the standardized BI-RADS and breast edema score on T2-weighted MRI. Univariable and multivariable logistic regression analyses were performed to assess variables association with pCR according to residual cancer burden. Random forest classifiers were trained to predict pCR on a random split including 70% of the database and were validated on the remaining cases. RESULTS Among 129 BC, 59 (46%) achieved pCR after NAC (luminal (n = 7/37, 19%), triple negative (n = 30/55, 55%), HER2 + (n = 22/37, 59%)). Clinical and biological items associated with pCR were BC subtype (p < 0.001), T stage 0/I/II (p = 0.008), higher Ki67 (p = 0.005), and higher tumor-infiltrating lymphocytes levels (p = 0.016). Univariate analysis showed that the following MRI features, oval or round shape (p = 0.047), unifocality (p = 0.026), non-spiculated margins (p = 0.018), no associated non-mass enhancement (p = 0.024), and a lower MRI size (p = 0.031), were significantly associated with pCR. Unifocality and non-spiculated margins remained independently associated with pCR at multivariable analysis. Adding significant MRI features to clinicobiological variables in random forest classifiers significantly increased sensitivity (0.67 versus 0.62), specificity (0.69 versus 0.67), and precision (0.71 versus 0.67) for pCR prediction. CONCLUSION Non-spiculated margins and unifocality are independently associated with pCR and can increase models performance to predict BC response to NAC. CLINICAL RELEVANCE STATEMENT A multimodal approach integrating pretreatment MRI features with clinicobiological predictors, including tumor-infiltrating lymphocytes, could be employed to develop machine learning models for identifying patients at risk of non-response. This may enable consideration of alternative therapeutic strategies to optimize treatment outcomes. KEY POINTS • Unifocality and non-spiculated margins are independently associated with pCR at multivariable logistic regression analysis. • Breast edema score is associated with MR tumor size and TIL expression, not only in TN BC as previously reported, but also in luminal BC. • Adding significant MRI features to clinicobiological variables in machine learning classifiers significantly increased sensitivity, specificity, and precision for pCR prediction.
Collapse
Affiliation(s)
- Caroline Malhaire
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France.
- Institut Curie, Research Center, U1288-LITO, Inserm, Paris-Saclay University, 91401, Orsay, France.
| | - Fatine Selhane
- Gustave Roussy, Department of Imaging, Paris-Saclay University, 94805, Villejuif, France
| | | | - Vincent Cockenpot
- Pathology Unit, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon, France
| | - Pia Akl
- Women Imaging Unit, HCL, Radiologie du Groupement Hospitalier Est, 3 Quai Des Célestins, 69002, Lyon, France
| | - Enora Laas
- Department of Surgical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Audrey Bellesoeur
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Catherine Ala Eddine
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Melodie Bereby-Kahane
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Julie Manceau
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Delphine Sebbag-Sfez
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Jean-Yves Pierga
- Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | - Fabien Reyal
- Department of Surgical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France
| | | | - Herve Brisse
- Department of Medical Imaging, Institut Curie, PSL Research University, 26 Rue d'Ulm, 75005, Paris, France
| | - Frederique Frouin
- Institut Curie, Research Center, U1288-LITO, Inserm, Paris-Saclay University, 91401, Orsay, France
| |
Collapse
|
2
|
Calaminus G, Bison B, Conter CF, Frappaz D, Peyrl A, Gerber NU, Müller JE, Ajithkumar T, Morana G, Cross J, Pietsch T, Smith C, Solem K, Devenney I, Garre ML, Brisse H, Zimmermann M, Kortmann RD, Alapetite C, Nicholson J. GCT-11. 24 Gy whole ventricular radiotherapy alone is sufficient for disease control in localised germinoma in CR after initial chemotherapy – final of the SIOP CNS GCT II study. Neuro Oncol 2022. [PMCID: PMC9165221 DOI: 10.1093/neuonc/noac079.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
SIOP CNS GCT II aimed to establish if 24 Gy Whole Ventricular Radiotherapy (WVRT) in localised germinoma is sufficient for tumour control. After central review of radiological response after ‘CarboPEI’ chemotherapy, patients in complete remission (CR) were consolidated with 24 Gy WVRT. Between 2/2012 and 7/2018, 194 patients from 8 European countries with histologically-confirmed fully-staged localised germinoma were registered, of whom 167 were protocol pts. CR after chemotherapy was achieved in 65 patients, Of the 102 patients not in CR after chemotherapy 91 had partial remission (PR), 8 stable disease (SD), 3 progressive disease (PD). All 65 patients in CR received 24 Gy WVRT alone; two of these relapsed, both locally, 7 and 12 months after diagnosis. Of the 102 non-CR patients after chemotherapy, 91 with PR and 8 with SD received 24 Gy WVRT and 16 Gy boost, of which five relapsed (four local, one distant) 2 -7 years from diagnosis. One additional patient who remained in CR died of infection in CR, 4 years after Dx. In three patients with PD all received 24 Gy ventricular irradiation with varying tumour boosts. 16-30 Gy, no relapses occurred. Median follow-up of the whole group was 4,2 years. 4- years event-free survival (EFS) for patients in CR treated with WVRT only (n=65) was 97% (standard error 2%). 4-years EFS for patients with non-CR ( WVRT 24 Gy and 16 Gy to 30 Gy tumour boost) (n=102) was 95% (standard error 2%). Localised germinoma in CR after chemotherapy had an excellent outcome with 24 Gy WVRT alone. 24 Gy WVRT is therefore considered the standard consolidation treatment in this group and should be used as the standard for further treatment studies in localised germinoma evaluating the recent international consensus on radiological response criteria ( Lancet Oncology accepted).
Collapse
Affiliation(s)
| | - Brigitte Bison
- Institute for Diagnostic and Interventional Neuroradiology University Hospital , Augsburg , Germany
| | | | - Didier Frappaz
- Institute d`Hemato-Oncologie Pediatrique , Lyon , France
| | - Andreas Peyrl
- Department of Paediatrics, Medical University of Vienna , Vienna , Austria
| | - Nicolas U Gerber
- The Center for Oncology at the University Children`s Hospital Zurich, Department of Oncology , Zurich , Switzerland
| | | | - Thankamma Ajithkumar
- Department of Clinical Oncology, Cambridge University Hospitals , Cambridge , United Kingdom
| | - Giovanni Morana
- Department of Neuroscience, University of Turin , Turin , Italy
| | - Justin Cross
- Department of Radiology, Cambridge University Hospitals , Cambridge , United Kingdom
| | - Torsten Pietsch
- Department of Neuropathology, DGNN Brain Tumour Reference Centre, University of Bonn , Bonn , Germany
| | - Colin Smith
- Academic Neuropathology, University of Edinburghy , Edinburgh , United Kingdom
| | - Kristin Solem
- Department for Children and Adolescents, St. Olav University Hospital of Trondheim , Trondheim , Norway
| | - Irenne Devenney
- Department of Paediatric Oncology, BOND Linköping University Hospital, Linköping, Sweden
| | - Maria Luisa Garre
- Unit of Neurooncology, Department of Haemato-Oncology, Gaslini, Children′s Hospital , Genova , Italy
| | - Herve Brisse
- Imaging Department, Institute Curie , Paris , France
| | - Martin Zimmermann
- Department of Paediatric Haematology/Oncology, Hannover Medical School , Hannover , Germany
| | | | - Claire Alapetite
- Radiation Oncology Department Institute Curie, Paris and Proton Centre, Orsay Paris , Paris , France
| | - James Nicholson
- Department of Paediatric Oncology, Cambridge University Hospital , Cambridge , United Kingdom
| |
Collapse
|
3
|
Moulin B, Servois V, Dbjay J, Dutertre G, Thery L, Bouleuc C, Marchal T, Laouisset C, Burnod A, Smadja J, Brisse H. CT-Guided Percutaneous Vertebroplasty of the Cervico-Thoracic Junction for the Management of Pathologic Fracture or Symptomatic Lytic Lesion in Cancer Patients. Cardiovasc Intervent Radiol 2021; 45:244-248. [PMID: 34853875 DOI: 10.1007/s00270-021-03018-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Accepted: 09/29/2021] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The purpose of this retrospective observational study is to report author's experience in computed-tomography (CT)-guided percutaneous vertebroplasty (PV) of the cervicothoracic junction. METHODS The records of all consecutive patients treated by PV at levels C7, T1, T2, and T3 in a tertiary cancer center during year 2020 were extracted from the Institutional electronic archive. Following data were collected: demographics, indication for PV, procedure features, outcomes, and complications. Technical success was defined as when the trocar was placed into the vertebral body, allowing the injection of polymethyl-metacrylate (PMMA). RESULTS Eleven patients were identified who received PV on 14 levels. Mean procedure duration was 57 ± 22 min (range [31-142]). A "trans-pedicular approach at the targeted level" was used in 1 vertebra (7%), a "costotransverse approach, at the targeted level" was used in 1 vertebra (7%), a "transpedicular approach via the level below" was used in 3 vertebrae (22%), and a "costotransverse approach via the level below" was used in 9 vertebrae (64%). Meantime to deploy each trocar was 20 ± 5 min (range [12-32]). Technical success was achieved in 14/14 (100%) of vertebrae. Mean postoperative hospitalization duration was 1.9 ± 1.7 days (range [1-11]). According to CIRSE classification, no adverse event occurred. PMMA leakage occurred in two patients; both remained asymptomatic. CONCLUSION This study provides arguments in favor of safety and efficiency of CT-guided vertebroplasty of levels C7, T1, T2, and T3, for both trocar deployment and monitoring of the vertebral body filling during the PMMA injection.
Collapse
Affiliation(s)
- Benjamin Moulin
- Interventional Radiology Unit, Imaging Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.
| | - Vincent Servois
- Interventional Radiology Unit, Imaging Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Jonathan Dbjay
- Interventional Radiology Unit, Imaging Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Guillaume Dutertre
- Department of Surgery, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Laura Thery
- Palliative Care Unit, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Carole Bouleuc
- Palliative Care Unit, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Timothee Marchal
- Palliative Care Unit, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Celine Laouisset
- Palliative Care Unit, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Alexis Burnod
- Palliative Care Unit, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Jeremy Smadja
- Interventional Radiology Unit, Imaging Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Herve Brisse
- Interventional Radiology Unit, Imaging Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| |
Collapse
|
4
|
Moulin B, Brisse H, Dutertre G, Brenet O, Queinnec M, Cottu P, Zadegan F, Moreau S, Benchimol R, Cao K, Servois V. CT-guided vertebroplasty of first (C1) or second (C2) cervical vertebra using an electromagnetic navigation system and a transoral approach. Diagn Interv Imaging 2021; 102:571-575. [PMID: 33972193 DOI: 10.1016/j.diii.2021.04.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 12/19/2022]
Affiliation(s)
- Benjamin Moulin
- Interventional Radiology Unit, Imaging Department, Institut Curie, 75005 Paris, France.
| | - Herve Brisse
- Interventional Radiology Unit, Imaging Department, Institut Curie, 75005 Paris, France
| | - Guillaume Dutertre
- Interventional Radiology Unit, Imaging Department, Institut Curie, 75005 Paris, France
| | - Olivier Brenet
- Anesthesiology and Pain Management Unit, Institut Curie, 75005 Paris, France
| | - Marie Queinnec
- Anesthesiology and Pain Management Unit, Institut Curie, 75005 Paris, France
| | - Paul Cottu
- Medical Oncology Unit, Institut Curie, 75005 Paris, France
| | - Frederic Zadegan
- Orthopedic Surgery Unit, Institut Mutualiste Montsouris, 75014 Paris, France
| | - Sebastien Moreau
- Orthopedic Surgery Unit, Institut Mutualiste Montsouris, 75014 Paris, France
| | - Raphael Benchimol
- Interventional Radiology Unit, Imaging Department, Institut Curie, 75005 Paris, France
| | - Kim Cao
- Radiation Therapy Unit, Institut Curie, 75005 Paris, France
| | - Vincent Servois
- Interventional Radiology Unit, Imaging Department, Institut Curie, 75005 Paris, France
| |
Collapse
|
5
|
Bison B, Morana G, Mitra D, Brisse H, Faure-Conter C, Ajithkumar T, Alapetite C, Timmermann B, Nicholson J, Calaminus G, Murray M. GCT-20. EVALUATION OF NEURORADIOLOGICAL RESPONSE TO INDUCTION CHEMOTHERAPY FOR PATIENTS WITH LOCALISED GERMINOMA IN THE SIOP CNS GCT II TRIAL. Neuro Oncol 2020. [PMCID: PMC7715693 DOI: 10.1093/neuonc/noaa222.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
INTRODUCTION The SIOP-CNS-GCT-96 trial demonstrated excellent survival for patients with germinoma. Localised patients received either craniospinal irradiation (CSI) 24Gy plus tumour-bed-boost 16 Gy or 2xcarboPEI chemotherapy (carboplatin/etoposide alternating with etoposide/ifosfamide) and focal-radiotherapy 40 Gy. Following trial closure, whole-ventricular-irradiation (WVI) was delivered with focal-radiotherapy to avoid ventricular relapse. Accordingly, current research priorities focus on reducing treatment burden and long-term neurocognitive sequelae. METHODS SIOP-CNS-GCT-II employed national central radiological review to assess whether dropping the 16Gy boost was safe for localized germinoma in complete-remission (CR) following 2xcarboPEI: i.e. no disease on clinical/marker/radiological assessment. Any abnormal thickening/enhancement after chemotherapy was to be classified as partial-remission (PR). Patients with less than CR after chemotherapy received a boost. RESULTS Shortly before trial closure (2018), it was noted that national CR rates were discrepant across the largest recruiting countries. For German patients, CR rates were ~80%, compared with ~30–40% for UK and France. A formal neuroradiology review was therefore convened. A total of 59 cases were randomly selected (UK, n=32; France, n=14 and Germany, n=13), including those deemed to be in CR and PR. Cases included those with disease at pituitary, pineal and bifocal sites. Both diagnostic scan and scan after induction chemotherapy were used for assessment. Detailed analysis is ongoing and will be presented. CONCLUSION Residual changes at both pituitary and pineal sites of uncertain significance may remain after chemotherapy. This process should facilitate consensus to define the best response criteria allowing treatment reduction for CNS germinoma for future clinical trials.
Collapse
Affiliation(s)
- Brigitte Bison
- Department of Neuroradiology, University of Wuersburg, Wuersburg, Germany
| | - Giovanni Morana
- Department of Neuroradiology, Gaslini Hospital, Genoa, Italy
| | - Dipayan Mitra
- Department of Neuroradiology, Royal Victoria Infirmary, Newcastle, United Kingdom
| | - Herve Brisse
- Imaging Department, Curie Institute, Paris, France
| | - Cecile Faure-Conter
- Department of Paediatric Haematology and Oncology, Institute of Paediatric Haematology and Oncology, Lyon, France
| | - Thankamma Ajithkumar
- Department of Radiation Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Claire Alapetite
- Department of Radiation Oncology, Curie Institute, Paris, France
| | - Beate Timmermann
- Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Essen, Germany
| | - James Nicholson
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| | - Gabriele Calaminus
- Department of Paediatric Haematology and Oncology, University Hospital, Bonn, Germany
| | - Matthew Murray
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
| |
Collapse
|
6
|
Calaminus G, Bison B, Faure-Conter C, Frappaz D, Peyrl A, Gerber N, Müller JE, Thankamma A, Mitra D, Cross J, Pietsch T, Smith C, Solem K, Devenney I, Garre ML, Brisse H, Zimmermann M, Kortmann RD, Alapetite C, Nicholson J. GCT-76. 24Gy WHOLE VENTRICULAR RADIOTHERAPY ALONE IS SUFFICIENT FOR DISEASE CONTROL IN LOCALISED GERMINOMA IN CR AFTER INITIAL CHEMOTHERAPY – EARLY RESULTS OF THE SIOP CNS GCT II STUDY. Neuro Oncol 2020. [PMCID: PMC7715895 DOI: 10.1093/neuonc/noaa222.292] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
SIOP CNS GCT II aimed to establish if 24Gy Whole Ventricular Radiotherapy (WVRT) in localised germinoma is sufficient for tumour control. After central review of radiological response after ‘CarboPEI’ chemotherapy, patients in complete remission (CR) were consolidated with 24Gy WVRT. Between 2/2012 and 7/2018, 182 patients from 8 European countries with histologically-confirmed fully-staged localised germinoma were registered. 70 patients were in CR after chemotherapy, 98 in partial remission (PR), seven had stable disease, two progressive disease, and in five no response data were documented. Of the 70 patients in CR, 58 received 24Gy WVRT alone; two of these relapsed, one local and one disseminated, two and six years after diagnosis. Of the 98 patients in PR after chemotherapy, 86 received 24Gy WVRT and 16Gy boost, of which five relapsed (three local, two distant) 12–24 months from diagnosis. Twelve patients in each of the CR/PR groups received non-protocol or undocumented radiotherapy fields/doses. Median follow-up was 3.7 years. Event-free survival (EFS) for patients in CR and with WVRT only (n=58) was 98% at 4 years. 4-years EFS of patients with PR and WVRT 24Gy and 16Gy tumor boost (n=86) was 95%. Localised germinoma in CR after chemotherapy had an excellent outcome with 24Gy WVRT alone; 24GY WVRT can therefore be considered standard consolidation treatment in this group. International consensus on radiological response criteria is of utmost importance to avoid over- and undertreatment of such patients and to pave the way for further treatment reduction in this group of patients.
Collapse
Affiliation(s)
- Gabriele Calaminus
- University Children’s Hospital Bonn, Dep, of Paediatric Haematology and Oncology, Bonn, Germany
| | - Brigitte Bison
- Institute for Diagnostic and Interventional Neuroradiology, University Hospital Würzburg, Würzburg, Germany
| | | | | | - Andreas Peyrl
- Department of Pediatrics, Medical University of Vienna, Vienna, Austria
| | - Nicolas Gerber
- The Center for Oncology at the University Children’s Hospital Zurich, Department of Oncology, Zurich, Switzerland
| | - Jans-Enno Müller
- University Children’s Hospital Bonn, Dep, of Paediatric Haematology and Oncology, Bonn, Germany
| | - Ajithkumar Thankamma
- Department of Clinical Oncology, Cambridge University Hospitals, Cambridge, United Kingdom
| | - Dipayan Mitra
- Department of Radiology, University of Newcastle, Newcastle, United Kingdom
| | - Justin Cross
- Department of Radiology, Cambridge University Hospitals, Cambridge, United Kingdom
| | - Torsten Pietsch
- Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn, Bonn, Germany
| | - Colin Smith
- Academic Neuropathology, University of Edinburgh, Edinburgh, United Kingdom
| | - Kristin Solem
- Dept for Children and Adolescents, St, Olav University Hospital of Trondheim, Trondheim, Norway
| | - Irene Devenney
- Dept, Pediatric Oncology, BOND Linköping University Hospital, Linköping, Sweden
| | - Maria Luisa Garre
- Unit of Neurooncology, Department of Haemato-Oncology Gaslini Children’s Hospital, Genova, Italy
| | - Herve Brisse
- Imaging Department, Institut Curie, Paris, France
| | - Martin Zimmermann
- Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
| | | | - Claire Alapetite
- Radiation Oncology Department Institut Curie, Paris & Proton Centre, Orsay, Paris, France
| | - James Nicholson
- Department of Paediatric Oncology, Cambridge University Hospitals, Cambridge, United Kingdom
| |
Collapse
|
7
|
Dicker A, Shen C, De Baere T, Hoffmann C, Welsh J, Rolland Y, Doger B, Den R, Trabulsi E, Lallas C, Seiwert T, Fernando N, Iannessi A, Pilleul F, Tetreau R, Rutkowski P, Papai Z, Brisse H. Hafnium Oxide Nanoparticles Activated By Radiotherapy: Potential for Local Treatment of a Wide Variety of Solid Tumors. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Fouque O, Kind M, Boulet B, Brisse H, Kemel S, Genah I, Taieb S, Stoeckle E, Meeus P, Lae M, Ranchère-Vince D, Blay JY, Coindre JM, Laredo JD, Bonvalot S. Stratégie diagnostique devant une tumeur graisseuse des tissus mous de l’adulte. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/j.jidi.2017.11.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
9
|
Choucair ML, Brisse H, Freneaux P, Lumbroso L, Chevrier M, Doz FP, Aerts I. Management of uni- or bilateral retinoblastoma with radiologic optic nerve invasion at diagnosis. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.10551] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10551 Background: To evaluate treatment and outcome of patients with uni- or bilateral retinoblastoma (RB) with radiologic optic nerve invasion (RONI) at diagnosis. Methods: Retrospective clinical, radiological and histological review of patients with uni- or bilateral RB with RONI at diagnosis treated in the Institut Curie. Results: Between 1997 and 2014, 936 patients with RB were treated in the Institut Curie. Eleven patients had detectable RONI confirmed by Computed Tomography and/or Magnetic Resonance Imaging. RB was unilateral in 10/11 patients, bilateral in 1. Median age at diagnosis was 29 months (range 12-96). The patient with the bilateral RB had a unilateral RONI. Nine patients had ON enhancement and 3 had meningeal sheath enhancement. Nine received neoadjuvant chemotherapy (CT) and 2 had a primary enucleation. Partial response to neoadjuvant CT was obtained for all the patients. Enucleation was performed in 10/11 patients, by anterior approach in 3 patients, by anterior and subfrontal approach in 7 patients. Three patients had positive ON margin and among them, 2 were primary enucleated. All enucleated patients received adjuvant treatment (conventional CT: 10, High Dose CT: 7 and radiotherapy: 5). Three patients died of meningeal progression (2 during treatment and 1 during the first year after treatment). The patient with the bilateral RB was lost to follow up just after a meningeal progression during treatment. Seven are still alive (median follow up: 8 years, range : 1.5-17.5). Conclusions: Neoadjuvant CT has an important place in the management of unilateral RB with RONI at diagnosis. Pretreatment accurate staging by orbital and brain MRI is mandatory, as well as preoperative reassessment. Surgery should be performed by experienced ophthalmologists and if necessary neurosurgical team in order to obtain the best conditions for a tumor-free resection margin in patients with RONI.
Collapse
Affiliation(s)
| | | | | | - Livia Lumbroso
- Department of Ophthalmology, Institut Curie, Paris, France
| | | | | | | |
Collapse
|
10
|
Desjardins L, Angi M, Levy C, Lumbroso Le Rouic L, Aerts I, Freneaux P, Brisse H, Cassoux N. New challenges in retinoblastoma treatment. Acta Ophthalmol 2016. [DOI: 10.1111/j.1755-3768.2016.0703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Journy N, Roué T, Cardis E, Le Pointe HD, Brisse H, Chateil JF, Laurier D, Bernier MO. Childhood CT scans and cancer risk: impact of predisposing factors for cancer on the risk estimates. J Radiol Prot 2016; 36:N1-7. [PMID: 26878249 DOI: 10.1088/0952-4746/36/1/n1] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
To investigate the role of cancer predisposing factors (PFs) on the associations between paediatric computed tomography (CT) scan exposures and subsequent risk of central nervous system (CNS) tumours and leukaemia. A cohort of children who underwent a CT scan in 2000-2010 in 23 French radiology departments was linked with the national childhood cancers registry and national vital status registry; information on PFs was retrieved through hospital discharge databases. In children without PF, hazard ratios of 1.07 (95% CI 0.99-1.10) for CNS tumours (15 cases) and 1.16 (95% CI 0.77-1.27) for leukaemia (12 cases) were estimated for each 10 mGy increment in CT x-rays organ doses. These estimates were similar to those obtained in the whole cohort. In children with PFs, no positive dose-risk association was observed, possibly related to earlier non-cancer mortality in this group. Our results suggest a modifying effect of PFs on CT-related cancer risks, but need to be confirmed by longer follow-up and other studies.
Collapse
Affiliation(s)
- N Journy
- Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Lumbroso-Le Rouic L, Savignoni A, Levy-Gabriel C, Aerts I, Cassoux N, Salviat F, Gauthier-Villars M, Freneaux P, Brisse H, Dendale R, Esteve M, Doz F, Desjardins L. Treatment of retinoblastoma: The Institut Curie experience on a series of 730 patients (1995 to 2009). J Fr Ophtalmol 2015; 38:535-41. [DOI: 10.1016/j.jfo.2015.04.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Accepted: 04/22/2015] [Indexed: 10/23/2022]
|
13
|
Abstract
The evaluation of bone marrow of patients treated for cancer is complicated by age-related changes in the distribution of normal (red) and fatty (yellow) marrow and by the changes induced by treatments. The treatments used in oncology modify pathological marrow but also normal marrow and may sometimes lead to complications. The knowledge of bone marrow physiological status and post-therapeutic patterns is important for the interpretation of marrow disorders and effects of therapy.
Collapse
Affiliation(s)
- L. Ollivier
- />Department of Radiology, Institut Curie, 26 rue d’Ulm, 75248 Paris, Cedex 05, France
| | - H. Brisse
- />Department of Radiology, Institut Curie, 26 rue d’Ulm, 75248 Paris, Cedex 05, France
| | - J. Leclère
- />Department of Radiology, Institut Gustave Roussy, Villejuif, France
| |
Collapse
|
14
|
Journy N, Rehel JL, Ducou Le Pointe H, Lee C, Brisse H, Chateil JF, Caer-Lorho S, Laurier D, Bernier MO. Are the studies on cancer risk from CT scans biased by indication? Elements of answer from a large-scale cohort study in France. Br J Cancer 2014; 112:185-93. [PMID: 25314057 PMCID: PMC4453597 DOI: 10.1038/bjc.2014.526] [Citation(s) in RCA: 143] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Revised: 09/08/2014] [Accepted: 09/09/2014] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Recent epidemiological results suggested an increase of cancer risk after receiving computed tomography (CT) scans in childhood or adolescence. Their interpretation is questioned due to the lack of information about the reasons for examination. Our objective was to estimate the cancer risk related to childhood CT scans, and examine how cancer-predisposing factors (PFs) affect assessment of the radiation-related risk. METHODS The cohort included 67,274 children who had a first scan before the age of 10 years from 2000 to 2010 in 23 French departments. Cumulative X-rays doses were estimated from radiology protocols. Cancer incidence was retrieved through the national registry of childhood cancers; PF from discharge diagnoses. RESULTS During a mean follow-up of 4 years, 27 cases of tumours of the central nervous system, 25 of leukaemia and 21 of lymphoma were diagnosed; 32% of them among children with PF. Specific patterns of CT exposures were observed according to PFs. Adjustment for PF reduced the excess risk estimates related to cumulative doses from CT scans. No significant excess risk was observed in relation to CT exposures. CONCLUSIONS This study suggests that the indication for examinations, whether suspected cancer or PF management, should be considered to avoid overestimation of the cancer risks associated with CT scans.
Collapse
Affiliation(s)
- N Journy
- Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France
| | - J-L Rehel
- Medical Radiation Protection Expertise Unit, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France
| | - H Ducou Le Pointe
- Department of Paediatric Radiology, Trousseau University Hospital, 26 avenue du Docteur Arnold-Netter, 75012 Paris, France
| | - C Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, 9000 Rockville Pike, 20892 Bethesda, MD, USA
| | - H Brisse
- Department of Radiology, Institut Curie, 11-13 rue Pierre et Marie Curie, 75005 Paris, France
| | - J-F Chateil
- Department of Paediatric Radiology, Pellegrin University Hospital, Place Amélie Raba-Léon, 33000 Bordeaux, France
| | - S Caer-Lorho
- Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France
| | - D Laurier
- Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France
| | - M-O Bernier
- Laboratory of Epidemiology, Institute for Radiological Protection and Nuclear Safety, BP 17, 92262 Fontenay-aux-Roses, France
| |
Collapse
|
15
|
Kannan V, Misra BK, Kapadia A, Bajpai R, Deshpande S, Almel S, Sankhe M, Desai K, Shaikh M, Anand V, Kannan A, Teo WY, Ross J, Bollo R, Seow WT, Tan AM, Kang SG, Kim DS, Li XN, Lau CC, Mohila CA, Adesina A, Su J, Ichimura K, Fukushima S, Matsushita Y, Tomiyama A, Niwa T, Suzuki T, Nakazato Y, Mukasa A, Kumabe T, Nagane M, Iuchi T, Mizoguchi M, Tamura K, Sugiyama K, Nakada M, Kanemura Y, Yokogami K, Matsutani M, Shibata T, Nishikawa R, Takami H, Fukushima S, Fukuoka K, Yanagisawa T, Nakamura T, Arita H, Narita Y, Shibui S, Nishikawa R, Ichimura K, Matsutani M, Sands S, Guerry W, Kretschmar C, Donahue B, Allen J, Matsutani M, Nishikawa R, Kumabe T, Sugiyama K, Nakamura H, Sawamura Y, Fujimaki T, Hattori E, Arakawa Y, Kawabata Y, Aoki T, Miyamoto S, Kagawa N, Hirayama R, Fujimoto Y, Chiba Y, Kinoshita M, Takano K, Eino D, Fukuya S, Nakanishi K, Yamamoto F, Hashii Y, Hashimoto N, Hara J, Yoshimine T, Murray M, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson J, Sumerauer D, Zapotocky M, Churackova M, Cyprova S, Zamecnik J, Malinova B, Kyncl M, Tichy M, Stary J, Lassen-Ramshad Y, von Oettingen G, Agerbaek M, Ohnishi T, Kohno S, Inoue A, Ohue S, Kohno S, Iwata S, Inoue A, Ohue S, Kumon Y, Ohnishi T, Acharya S, DeWees T, Shinohara E, Perkins S, Kato H, Fuji H, Nakasu Y, Ishida Y, Okawada S, Yang Q, Guo C, Chen Z, Alapetite C, Faure-Conter C, Verite C, Pagnier A, Laithier V, Entz-Werle N, Gorde-Grosjean S, Palenzuela G, Lemoine P, Frappaz D, Nguyen HA, Bui L, Ngoc, Cerbone M, Ederies A, Losa L, Moreno C, Sun K, Spoudeas HA, Nakano Y, Okada K, Kosaka Y, Nagashima T, Hashii Y, Kagawa N, Soejima T, Osugi Y, Sakamoto H, Hara J, Nicholson J, Alapetite C, Kortmann RD, Garre ML, Ricardi U, Saran F, Frappaz D, Calaminus G, Muda Z, Menon B, Ibrahim H, Rahman EJA, Muhamad M, Othman IS, Thevarajah A, Cheng S, Kilday JP, Laperriere N, Drake J, Bouffet E, Bartels U, Sakamoto H, Matsusaka Y, Watanabe Y, Umaba R, Hara J, Osugi Y, Alapetite C, Ruffier-Loubiere A, De Marzi L, Bolle S, Claude L, Habrand JL, Brisse H, Frappaz D, Doz F, Bourdeaut F, Dendale R, Mazal A, Fournier-Bidoz N, Fujimaki T, Fukuoka K, Shirahata M, Suzuki T, Adachi JI, Mishima K, Wakiya K, Matsutani M, Nishikawa R, Fukushima S, Yamashita S, Kato M, Nakamura H, Takami H, Suzuki T, Yanagisawa T, Mukasa A, Kumabe T, Nagane M, Sugiyama K, Tamura K, Narita Y, Shibui S, Shibata T, Ushijima T, Matsutani M, Nishikawa R, Ichimura K, Consortium IGA, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Calaminus G, Kortmann RD, Frappaz D, Alapetite C, Garre ML, Ricardi U, Saran FH, Nicholson J, Czech T, Nicholson J, Frappaz D, Kortmann RD, Alapetite C, Garre ML, Ricardi U, Saran F, Calaminus G, Hayden J, Bartels U, Calaminus G, Joseph R, Nicholson J, Hale J, Lindsay H, Kogiso M, Qi L, Yee TW, Huang Y, Mao H, Lin F, Baxter P, Su J, Terashima K, Perlaky L, Lau C, Parsons D, Chintagumpala M, Li XAN, Osorio D, Vaughn D, Gardner S, Mrugala M, Ferreira M, Keene C, Gonzalez-Cuyar L, Hebb A, Rockhill J, Wang L, Yamaguchi S, Burstein M, Terashima K, Ng HK, Nakamura H, He Z, Suzuki T, Nishikawa R, Natsume A, Terasaka S, Dauser R, Whitehead W, Adesina A, Sun J, Munzy D, Gibbs R, Leal S, Wheeler D, Lau C, Dhall G, Robison N, Judkins A, Krieger M, Gilles F, Park J, Lee SU, Kim T, Choi Y, Park HJ, Shin SH, Kim JY, Robison N, Dhir N, Khamani J, Margol A, Wong K, Britt B, Evans A, Nelson M, Grimm J, Finlay J, Dhall G. GERM CELL TUMOURS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Dumoucel S, Gauthier-Villars M, Stoppa-Lyonnet D, Parisot P, Brisse H, Philippe-Chomette P, Sarnacki S, Boccon-Gibod L, Rossignol S, Baumann C, Aerts I, Bourdeaut F, Doz F, Orbach D, Pacquement H, Michon J, Schleiermacher G. Malformations, genetic abnormalities, and Wilms tumor. Pediatr Blood Cancer 2014; 61:140-4. [PMID: 23970395 DOI: 10.1002/pbc.24709] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Accepted: 07/05/2013] [Indexed: 11/07/2022]
Abstract
BACKGROUND Wilms Tumor (WT) can occur in association with tumor predisposition syndromes and/or with clinical malformations. These associations have not been fully characterized at a clinical and molecular genetic level. This study aims to describe clinical malformations, genetic abnormalities, and tumor predisposition syndromes in patients with WT and to propose guidelines regarding indications for clinical and molecular genetic explorations. PROCEDURE This retrospective study analyzed clinical abnormalities and predisposition syndromes among 295 patients treated for WT between 1986 and 2009 in a single pediatric oncological center. RESULTS Clinically identified malformations and predisposition syndromes were observed in 52/295 patients (17.6%). Genetically proven tumor predisposition syndromes (n = 14) frequently observed were syndromes associated with alterations of the chromosome WT1 region such as WAGR (n = 6) and Denys-Drash syndromes (n = 3), syndromes associated with alterations of the WT2 region (Beckwith-Wiedeman syndrome, n = 3), and Fanconi anemia (n = 2). Hemihypertrophy and genito-urinary malformations (n = 12 and n = 16, respectively) were the most frequently identified malformations. Other different syndromes or malformations (n = 10) were less frequent. Median age of WT diagnosis was significantly earlier for children with malformations than those without (27 months vs. 37 months, P = 0.0009). There was no significant difference in terms of 5-year EFS and OS between WT patients without or with malformations. CONCLUSIONS The frequency of malformations observed in patients with WT underline the need of genetic counseling and molecular genetic explorations for a better follow-up of these patients, with a frequently good outcome. A decisional tree, based on clinical observations of patients with WT, is proposed to guide clinicians for further molecular genetic explorations.
Collapse
Affiliation(s)
- S Dumoucel
- Department of Pediatric Oncology, Institut Curie, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Hankinson T, Fields E, Handler M, Foreman N, Liu A, Muller HL, Gebhardt U, Warmuth-Metz M, Kortmann RD, Faldum A, Pietsch T, Sorensen N, Calaminus G, Muller HL, Gebhardt U, Maroske J, Hanisch E, Muller HL, Gebhardt U, Pohl F, Kortmann RD, Faldum A, Warmuth-Metz M, Pietsch T, Calaminus G, Sorensen N, Muller HL, Enriori PJ, Gebhardt U, Hinney A, Hebebrandt J, Reinehr T, Cowley M, Roth C, Rosenfeld A, Arrington D, Etzl M, Miller J, Gieseking A, Dvorchik I, Kaplan A, Jakacki R, Yeung J, Panigrahy A, Pollack I, Mallucci C, Pizer B, Didi M, Blair J, Upadrasta S, Doss A, Avula S, Pettorini B, Alapetite C, Puget S, Ruffier A, Habrand JL, Bolle S, Noel G, Nauraye C, De Marzy L, Boddaert N, Brisse H, Sainte-Rose C, Zerah M, Boetto S, Laffond C, Chevignard M, Grill J, Doz F, Jalali R, Gupta T, Goswami S, Shah N, Golambade N, Ikazoboh EC, Dattani M, Spoudeas H, Confer M, McNall-Knapp R, Krishnan S, Gross N, Keole S, Ormandy D, Alston R, Kamaly-Asl I, Gattamaneni R, Birch J, Estlin E, Kiehna E, Laws E, Oldfield E, Jane J. CRANIOPHARYNGIOMA. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Murray J, Braly E, Head H, Donahue D, Rush S, Stence N, Liu A, Kleinhenz J, Bison B, Pietsch T, von Hoff K, von Bueren A, Rutkowski S, Warmuth-Metz M, Jaspan T, Brisse H, Potepan P, Warmuth-Metz M, Berg F, Bison B, Pietsch T, Gerber N, Rutkowski S, Warmuth-Metz M, Sugiyama K, Kurisu K, Kajiwara Y, Takayasu T, Saito T, Hanaya R, Yamasaki F, Vicente J, Fuster-Garcia E, Tortajada S, Garcia-Gomez JM, Davies N, Natarajan K, Wilson M, Grundy RG, Wesseling P, Monleon D, Celda B, Robles M, Peet AC, Perret C, Boltshauser E, Scheer I, Kellenberger C, Grotzer M, Steffen-Smith E, Venzon D, Bent R, Baker E, Shandilya S, Warren K, Shih CS, West J, Ho C, Porter D, Wang Y, Saykin A, McDonald B, Arfanakis K, Warren K, Vezina G, Hargrave D, Poussaint TY, Goldman S, Packer R, Wen P, Pollack I, Zurakowski D, Kun L, Prados M, Kieran M, Eckel L, Keating G, Giannini C, Wetjen N, Patton A, Steffen-Smith E, Sarlls J, Pierpaoli C, Walker L, Venzon D, Bent R, Warren K, Perreault S, Lober R, Yeom K, Carret AS, Vogel H, Partap S, Fisher P, Gill SK, Wilson M, Davies NP, MacPherson L, Arvanitis TN, Peet AC, Davies N, Gill S, Wilson M, MacPherson L, Arvanitis T, Peet A, Hayes L, Jones R, Mazewski C, Aguilera D, Palasis S, Bendel A, Patterson R, Petronio J, Meijer L, Jaspan T, Grundy RGG, Walker DA, Robison N, Grant F, Treves ST, Bandopadhayay P, Manley P, Chi S, Zimmerman MA, Chordas C, Goumnerova L, Smith E, Scott M, Ullrich NJ, Poussaint T, Kieran M, Yang JC, Lightner DD, Khakoo Y, Wolden SL, Smee R, Zhao C, Spencer-Trotter B, Hallock A, Konski A, Bhambani K, Mahajan A, Jones J, Ketonen L, Paulino A, Ater J, Grosshans D, Dauser R, Weinberg J, Chintagumpala M, Dvir R, Elhasid R, Corn B, Tempelhoff H, Matceyevsky D, Makrin V, Shtraus N, Yavetz D, Constantini S, Gez E, Yu ES, Kim YJ, Park HJ, Kim HJ, Shin SH, Kim JH, Kim JY, Lee YK, Fiore MR, Sanne C, Mandeville HC, Saran FH, Greenspoon J, Duckworth J, Singh S, Scheinemann K, Whitton A, Gauvain K, Geller T, Elbabaa S, Dombrowski J, Wong K, Olch A, Davidson TB, Venkatramani R, Haley K, Zaky W, Dhall G, Finlay J, Bishop MW, Hummel TR, Leach J, Minturn J, Breneman J, Stevenson C, Wagner L, Sutton M, Miles L, Fouladi M, Goldman S. RADIOLOGY. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Hilbert M, Mary P, Larroquet M, Serinet MO, Helfre S, Brisse H, Coulomb A, Orbach D. Alveolar soft part sarcoma in childhood: is Sunitinib-Sutent® treatment an effective approach? Pediatr Blood Cancer 2012; 58:475-6. [PMID: 22234817 DOI: 10.1002/pbc.23303] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 07/13/2011] [Indexed: 11/09/2022]
|
20
|
Chantada G, Leal-Leal C, Brisse H, de Graaf P, Sitorus RS, Qaddoumi I, de Antoneli CB, Tacyildiz N, Fineman SL, Lumbroso L, Doz F. Is It Pre-Enucleation Chemotherapy or Delayed Enucleation of Severely Involved Eyes With Intraocular Retinoblastoma That Risks Extraocular Dissemination and Death? J Clin Oncol 2011; 29:3333-4; author reply 3335-6. [DOI: 10.1200/jco.2011.35.9190] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Guillermo Chantada
- Grupo de America Latina de Oncología Pediátrica; Hospital Juan Pedro Garrahan, Buenos Aires, Argentina
| | - Carlos Leal-Leal
- Grupo Mexicano para el Tratamiento del Retinoblastoma; Instituto Nacional de Pediatría, Mexico Distrito Federal, Mexico
| | - Herve Brisse
- European Retinoblastoma Imaging Collaboration; Institut Curie, Paris, France
| | - Pim de Graaf
- European Retinoblastoma Imaging Collaboration; Vrije Universiteit University Medical Center, Amsterdam, the Netherlands
| | - Rita S. Sitorus
- Indonesian Retinoblastoma Protocol; Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
| | | | | | - Nurdan Tacyildiz
- Ankara University Retinoblastoma Group; Ankara University, School of Medicine, Ankara, Turkey
| | - Sandra Luna Fineman
- Asociacion de Hemato-Oncologia Pediátrica de Centro America; Stanford University, Palo Alto, CA
| | - Livia Lumbroso
- Institut Curie Paris and University Paris Descartes, Paris, France
| | - François Doz
- Institut Curie Paris and University Paris Descartes, Paris, France
| |
Collapse
|
21
|
Bernier MO, Mezzarobba M, Maupu E, Caër-Lorho S, Brisse H, Laurier D, Brunelle F, Chatellier G. Utilisation des données du programme de médicalisation des systèmes d’information dans les études épidémiologiques : individualisation des patients présentant un cancer ou une pathologie à risque de cancer. Rev Epidemiol Sante Publique 2011. [DOI: 10.1016/j.respe.2011.03.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
22
|
Pierrat N, Lasalle S, Brisse H. Iterative reconstruction in computed tomography: potential, dose benefit and impact on image quality. Phys Med 2011. [DOI: 10.1016/j.ejmp.2011.06.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
23
|
Thomson TA, Klijanienko J, Couturier J, Brisse H, Pierron G, Freneaux P, Sastre-Garau X, Lagace R, Bourdeaut F. Fine-needle aspiration of renal and extrarenal rhabdoid tumors. Cancer Cytopathol 2010; 119:49-57. [DOI: 10.1002/cncy.20121] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2010] [Revised: 07/24/2010] [Accepted: 09/14/2010] [Indexed: 01/03/2023]
|
24
|
Alapetite C, Brisse H, Patte C, Raquin MA, Gaboriaud G, Carrie C, Habrand JL, Thiesse P, Cuilliere JC, Bernier V, Ben-Hassel M, Frappaz D, Baranzelli MC, Bouffet E. Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neuro Oncol 2010; 12:1318-25. [PMID: 20716594 DOI: 10.1093/neuonc/noq093] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Over the last two decades, chemotherapy has been introduced in protocols for patients with intracranial germinoma with the objective of reducing the volume and the dose of irradiation without compromising survival rates. The aim of this work is to critically analyze the pattern of relapse in a cohort of patients with nonmetastatic germinoma prospectively treated with chemotherapy followed by focal field radiation. Data of all germinoma patients registered in the French protocol for intracranial germ cell tumors between 1990 and 1999 were reviewed. The pattern of relapse, management, and outcome were analyzed in 10 of 60 patients who developed a recurrence after initial treatment. In 9 patients, the site of recurrence was local or loco-regional, notably in the periventricular area for 8. One patient only had isolated distant leptomeningeal relapse. The review of the sites of relapse suggests that most recurrences could have been avoided with a larger ventricular field of radiation. Treatment at first relapse included chemotherapy (10 patients), high-dose chemotherapy and stem cell transplant (8 patients), and/or radiation therapy (4 patients). Five patients experienced a second relapse. At a median follow-up of 72 months since the first relapse, 8 patients are alive in second or third remission. This review identified an excess of periventricular relapses when the focal field of radiation is used in the combined management of germinoma. These relapses are predominantly marginal or outside radiation fields. Ventricular field radiation appears a logical alternative to decrease the incidence of such relapses. Future trials should aim at better identifying patients who may benefit from local and ventricular radiation, respectively.
Collapse
|
25
|
Desjardins L, Gerber S, O.Berges, IbaZizen M, Gabriel CL, LeRouic LL, Brisse H. Diagnostic des hématomes sous-rétiniens spontanés isolés ou associés à une dégénérescence maculaire liée à l’âge. Étude rétrospective de 95 cas. J Fr Ophtalmol 2009; 32:621-8. [DOI: 10.1016/j.jfo.2009.09.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2009] [Accepted: 07/22/2009] [Indexed: 11/26/2022]
|
26
|
Edeline V, Bonardel G, Brisse H, Foehrenbach H, Pacquement H, Maszelin P, Gaillard JF, Michon J, Neuenschwander S. Prospective study of 18F-FDG PET in pediatric mediastinal lymphoma: A single center experience. Leuk Lymphoma 2009; 48:823-6. [PMID: 17454646 DOI: 10.1080/10428190601162854] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Vahedi A, Lumbroso-Le Rouic L, Levy Gabriel C, Doz F, Aerts I, Brisse H, Berges O, Iba Zizen MT, Desjardins L. [Differential diagnosis of retinoblastoma: a retrospective study of 486 cases]. J Fr Ophtalmol 2008; 31:165-72. [PMID: 18401317 DOI: 10.1016/s0181-5512(08)70349-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
OBJECTIVES Detail the most frequent problems encountered in the differential diagnosis of retinoblastoma. PATIENTS and method: We conducted a retrospective study on the children referred to the Curie Institute for suspicion of retinoblastoma between 2000 and 2006. Diagnosis was made by fundus examination using the indirect ophthalmoscope, ultrasonography, and MRI. RESULTS Of the 486 children seen during this period, 408 had unilateral or bilateral retinoblastoma and 78 (16%) had another lesion: Coats disease (20 children, 25%), congenital malformations (23 children, 30%; coloboma, PHPV, microphthalmia, isolated or associated with retinal dysplasia), other tumors (10 children, 13%; astrocytomas and medulloepithelioma), combined hamartomas (six children, 8%), inflammatory diseases (six children, 8%) (Toxocara canis, cat scratch eye disease, or toxoplasmosis), and other diseases (13 children, 16%; corneal opacities, congenital cataract, or retinal detachment). DISCUSSION Compared to previous series, this study shows the proportion of erroneous diagnosis has lowered (16%) compared to earlier studies by Balmer (1986; 30%), and Shields (1991; 42%). No cases of retinopathy of prematurity were seen in our series, demonstrating that screening is good or of a lower frequency in France. The frequency of PHPV has dropped. Coats disease remains a frequent and sometimes difficult diagnosis to make, particularly in advanced stages of the disease.
Collapse
|
28
|
Affiliation(s)
- J Lenoir
- AgroParisTech, UMR 1092, Laboratoire d'Etude des Ressources Forêt-Bois (LERFoB), 14 rue Girardet, F-54000 Nancy, France.
| | | | | | | | | |
Collapse
|
29
|
Krug P, Schleiermacher G, Michon J, Valteau-Couanet D, Brisse H, Peuchmaur M, Sarnacki S, Martelli H, Desguerre I, Tardieu M. SFP-12 – Neurologie – Evolution neurologique des enfants atteints de syndrome opso-myoclonique associé ou non à un neuroblastome. Arch Pediatr 2008. [DOI: 10.1016/s0929-693x(08)72080-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
30
|
Gerber S, Ollivier L, Leclère J, Vanel D, Missenard G, Brisse H, de Pinieux G, Neuenschwander S. Imaging of sacral tumours. Skeletal Radiol 2008; 37:277-89. [PMID: 18034341 DOI: 10.1007/s00256-007-0413-4] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Revised: 09/10/2007] [Accepted: 10/09/2007] [Indexed: 02/02/2023]
Abstract
All components of the sacrum (bone, cartilage, bone marrow, meninges, nerves, notochord remnants, etc.) can give rise to benign or malignant tumours. Bone metastases and intraosseous sites of haematological malignancies, lymphoma and multiple myeloma are the most frequent aetiologies, while primary bone tumours and meningeal or nerve tumours are less common. Some histological types have a predilection for the sacrum, especially chordoma and giant cell tumour. Clinical signs are usually minor, and sacral tumours are often discovered in the context of nerve root or pelvic organ compression. The roles of conventional radiology, CT and MRI are described and compared with the histological features of the main tumours. The impact of imaging on treatment decisions and follow-up is also reviewed.
Collapse
Affiliation(s)
- S Gerber
- Department of Radiology, Institut Curie, 26 rue d'Ulm, 75248 Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Abstract
Positron emission tomography (PET)/computed tomography (CT) imaging is frequently requested in Oncology. Radiologists and nuclear medicine physicians are often asked to perform a panel of imaging examinations as part of the initial staging or follow-up of cancer patients. Medical imaging must therefore integrate polyvalent skills enabling imaging specialists to understand and interpret all types of images. In this context, PET imaging combined with non-enhanced CT, and diagnostic quality contrast-enhanced CT scan and optimisation of CT settings, is part of this multidisciplinary approach requiring the specific skills of a radiologist and a nuclear medicine physician. This approach must therefore be conducted in both directions: radiologists and nuclear medicine physicians should both know how to correlate PET and CT images, while preserving the specificities of each discipline. Radiologists need to be aware of several aspects of PET imaging: PET technology, the examination procedure and injection of iodinated contrast agent for high quality diagnostic CT, ideally followed by double interpretation of CT images, PET images and fused images. Radiologists should be familiar with PET imaging, as this procedure may be associated with several pitfalls and artefacts that need interpretation by a trained specialist. The authors analyse the examination technique of PET combined with non-enhanced and/or contrast-enhanced CT and the proposals for optimal interpretation of normal or pathological PET/CT fusion images.
Collapse
Affiliation(s)
- M Benamor
- Institut Curie, Departement d'imagerie, 75005 Paris, France.
| | | | | | | | | | | |
Collapse
|
32
|
Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, Ribeiro A, Mosseri V, Rubie H, Munzer C, Thomas C, Valteau-Couanet D, Auvrignon A, Plantaz D, Delattre O, Couturier J. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 2007; 97:238-46. [PMID: 17579628 PMCID: PMC2360301 DOI: 10.1038/sj.bjc.6603820] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Whereas neuroblastoma (NB) with MYCN amplification presents a poor prognosis, no single marker allows to reliably predict outcome in tumours without MYCN amplification. We report here an extensive analysis of 147 NB samples at diagnosis, without MYCN amplification, by chromosomal comparative genomic hybridisation (CGH), providing a comprehensive overview of their genomic imbalances. Comparative genomic hybridisation profiles showed gains or losses of entire chromosomes (type 1) in 71 cases, whereas partial chromosome gains or losses (type 2), including gain involving 17q were observed in 68 cases. Atypical profiles were present in eight cases. A type 1 profile was observed more frequently in localised disease (P<0.0001), and in patients of less than 12 months at diagnosis (P<0.0001). A type 2 genomic profile was associated with a higher risk of relapse in the overall population (log-rank test; P<0.0001), but also in the subgroup of patients with localised disease (log-rank test, P=0.007). In multivariate analysis, the genomic profile was the strongest independent prognostic factor. In conclusion, the genomic profile is of prognostic impact in patients without MYCN amplification, making it a help in the management of low-stage NB. Further studies using higher-resolution CGH are needed to better characterise atypical genomic alterations.
Collapse
|
33
|
Vahedi A, Lumbroso Le Rouic L, Levy Gabriel C, Baccouri R, Sastre X, Brisse H, Doz F, Aerts I, Desjardins L. 337 Rétinoblastome et pièges diagnostiques. J Fr Ophtalmol 2007. [DOI: 10.1016/s0181-5512(07)80149-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Brisse H, Sirinelli D, Chateil J, Cordoliani Y, Aubert B, Silberman B, Panuel M, Adamsbaum C. Inscrire la dose d’exposition dans les comptes-rendus radiologiques : pourquoi ? comment ? ACTA ACUST UNITED AC 2007; 88:411-4. [PMID: 17457278 DOI: 10.1016/s0221-0363(07)89843-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- H Brisse
- Département d'Imagerie, Institut Curie, 26 rue d'Ulm, Paris, France.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
Magnetic resonance imaging (MRI) is the best technique for bone marrow imaging. The MRI signal of bone marrow depends on the quantity of fat it contains and on its cellularity. Evaluation of marrow of patients treated for cancer is complicated by age and osseous site related changes in the distribution of normal haematopoietic (red) and fatty (yellow) marrow and by the changes induced by treatments: decrease in pathological cellularity, increase in fat proportion, conversion of red marrow to fatty marrow or, conversely, reconversion of fatty marrow in normal haematopoietic red marrow. The treatments used in oncology modify pathological marrow but also normal marrow and may sometimes lead to complications. These modifications may be focal or diffuse, homogeneous or patchy and symmetrical or asymmetric. The knowledge of bone marrow physiological status and post-therapeutic patterns is important for the interpretation of marrow disorders and effects of therapy and to avoid false-positive diagnosis of marrow metastases and tumour progression. The aim of this paper is to recall the MRI patterns of normal bone marrow and normal variations and to show the effects of treatments on bone tissue and normal bone marrow and treatment-related modifications on pathological marrow.
Collapse
Affiliation(s)
- L Ollivier
- Department of Radiology, Institut Curie, 26 rue d'Ulm, 75248 Paris, France.
| | | | | | | | | |
Collapse
|
36
|
Philippe-Chomette P, Orbach D, Brisse H, Aigrain Y, Berrebi D, El Ghoneimi A. [Rhabdomyosarcoma of the genitourinary sinus in children]. Ann Urol (Paris) 2006; 40:280-96. [PMID: 17100165 DOI: 10.1016/j.anuro.2006.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Genitourinary rhabdomyosarcoma (RMS) accounts for approximately 25% of all rhabdomyosarcomas. Management of RMS at this site has changed during the last 5 consecutive Intergroup Rhabdomyosarcoma (IRS) trials, with increasing emphasis of bladder and vaginal conservation. As more effective treatment regimens has improved survival, surgical approaches have evolved to less aggressive management of the primary tumour to improve conservation. Various combinations of chemotherapy, irradiation and surgery have resulted in a decreased late sequelae in the group of patients with sarcoma arising in the genitourinary tract.
Collapse
Affiliation(s)
- P Philippe-Chomette
- Service de chirurgie viscérale et urologique, Hôpital Robert Debré, 48, boulevard Sérurier, 75019 Paris, France.
| | | | | | | | | | | |
Collapse
|
37
|
Madre C, Orbach D, Baudouin V, Brisse H, Bessa F, Schleiermacher G, Pacquement H, Doz F, Michon J. Hypertension in childhood cancer: a frequent complication of certain tumor sites. J Pediatr Hematol Oncol 2006; 28:659-64. [PMID: 17023826 DOI: 10.1097/01.mph.0000212995.56812.bb] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
UNLABELLED The clinical features and management of severe hypertension (HT) (blood pressure > 99th percentile + 5 mm Hg) have been rarely described in pediatric oncology. OBJECTIVES Retrospective descriptive study of the case files of 31 patients followed in the Institut Curie Department of Pediatric Oncology between 1999 and 2004 and presenting severe HT at the time of diagnosis of their tumor. RESULTS The median age was 2 years 1 month (range: 3 mo to 6 y 8 mo). Median blood pressure was 99th percentile + 30 mm Hg (range: 99th percentile + 7 mm Hg to 99th percentile + 62 mm Hg). The tumors presented by these children were: Wilms tumor (n=17, ie, 20% of all Wilms tumors treated during this period), neuroblastoma (n=12, ie, 10% of all neuroblastomas treated during this period) or other tumors (n=2). HT was asymptomatic in all children. Initial management consisted of etiologic treatment by primary chemotherapy and/or surgical resection of the tumor, associated with antihypertensive therapy, initially administered by intravenous injection for 12 children (nicardipine, labetalol) and then orally in all children (calcium channel blockers, n=23; angiotensin-converting enzyme inhibitor, n=16; beta-blockers, n=4; alpha/beta-blockers, n=2; diuretics, n=1). Dual therapy was necessary in 7 cases and triple therapy was necessary in 1 case. The median duration of antihypertensive therapy was 40 days (range: 9 to 195). No child developed a serious complication of HT. CONCLUSIONS Initial HT is a frequent complication of Wilms tumor and neuroblastoma and affects young children (< 2.5 y). It is often severe, asymptomatic, but needs specific treatment and resolves after treatment of the tumor.
Collapse
|
38
|
Guesmi M, Sastre X, Desjardins L, Lumbroso L, Aerts I, Doz F, Asselain B, Bours D, Neuenschwander S, Brisse H. Depistage pre-operatoire de l’extension au nerf optique des retinoblastomes : correlation imagerie-pathologie. ACTA ACUST UNITED AC 2006. [DOI: 10.1016/s0221-0363(06)87307-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
39
|
|
40
|
Affiliation(s)
- H Brisse
- Service de radiodiagnostic, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | | |
Collapse
|
41
|
Brisse H. [The radiologic contribution to surgical aspects of kidney tumors in children]. JBR-BTR 2005; 88:250-3. [PMID: 16302339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Affiliation(s)
- H Brisse
- Département d'Imagerie, Institut Curie, Paris, France
| |
Collapse
|
42
|
Brisse H, Orbach D, Lassau N, Servois V, Doz F, Debray D, Helfre S, Hartmann O, Neuenschwander S. Portal vein thrombosis during antineoplastic chemotherapy in children: Report of five cases and review of the literature. Eur J Cancer 2004; 40:2659-66. [PMID: 15571949 DOI: 10.1016/j.ejca.2004.06.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2003] [Revised: 05/19/2004] [Accepted: 06/11/2004] [Indexed: 11/20/2022]
Abstract
We report five paediatric cases of portal vein thrombosis (PVT) occurring during chemotherapy, observed in two institutions over an 8-year time period. These children aged 2.5-15 years were treated for Burkitt's lymphoma, Ewing's tumour, small cell bone tumour or medulloblastoma. PVT was diagnosed on colour Doppler ultrasonography (US). In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing busulfan. In one case, PVT occurred in the absence of HVOD in a patient with pre-existing periportal lymphomatous infiltration. Four patients experienced persistent portal hypertension, which resulted in death in one. PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing busulfan and to be associated with HVOD.
Collapse
Affiliation(s)
- H Brisse
- Imaging Department, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Brisse H, Sirinelli D, Adamsbaum C, Chateil JF, Claudon M, Geoffray A, Petit P, Rausin L, Panuel M. [Medical irradiation of children. Beware of reaching a conclusion too fast]. J Radiol 2004; 85:1671-2. [PMID: 15669559 DOI: 10.1016/s0221-0363(04)97730-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
|
44
|
Adamsbaum C, Brisse H, Neuenschwander S. [Interpretation session in general radiology. Case No. 1: Pediatrics. Ovarian lymphoma]. J Radiol 2004; 85:426-8. [PMID: 15213657 DOI: 10.1016/s0221-0363(04)97606-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
|
45
|
de Lagausie P, Berrebi D, Michon J, Philippe-Chomette P, El Ghoneimi A, Garel C, Brisse H, Peuchmaur M, Aigrain Y. Laparoscopic adrenal surgery for neuroblastomas in children. J Urol 2003; 170:932-5. [PMID: 12913744 DOI: 10.1097/01.ju.0000081415.49550.01] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE The role of laparoscopy in children with neuroblastomas has not been fully defined. The laparoscopic approach to the adrenal gland is already largely used in adults and a few cases have been reported in children. We report the experience of a single surgical team center with laparoscopic adrenal surgery for neuroblastomas in children. MATERIALS AND METHODS Between September 2000 and October 2002 laparoscopic adrenalectomy for neuroblastoma was performed in 9 patients (6 girls and 3 boys) with a mean age of 38 months (range 2 months to 9 years). Two tumors were detected prenatally and 7 postnatally. Preoperative diagnosis was neuroblastoma stage I in 4 cases and stage IV in 3 cases, and nondetermined suprarenal calcified masses in 2 cases. A 4 or 5-trocar transperitoneal approach was used in all cases. The adrenal tumors were completely excised, placed into a plastic bag and removed through the umbilical trocar site. RESULTS All of the adrenal tumors were well encapsulated and completely excised. One of the 9 procedures was converted to open surgery because of adhesions to renal vessels. In 1 case a second hepatic localization was removed simultaneously, and in 3 cases 1 or more lymph nodes were resected. Average operative time was 85 minutes (range 45 to 170). There were no deaths. There were no postoperative complications, except 1 port site infection that was treated locally. Blood transfusion was not required. Average hospital stay was 4.5 days (range 2 to 10). Histological analysis of the 9 specimens (maximum length 6 cm) confirmed the diagnosis of neuroblastoma. N-myc status was studied in 8 of the 9 resected neuroblastomas and was amplified in 2 cases (both stage IV with preoperative biopsy). Average postoperative followup was 15 months (range 1 to 25). There was no local recurrence or metastasis, except in the case that required conversion to open surgery (local recurrence 7 months later). CONCLUSIONS Laparoscopic adrenalectomy for neuroblastoma is safe and feasible in children, with good results. Experience with advanced laparoscopic surgery is required to achieve this result in optimal oncological conditions. Our short-term results must be reevaluated at long term, and further studies are needed to compare laparoscopy to open surgical techniques.
Collapse
Affiliation(s)
- P de Lagausie
- Department of Pediatric Surgery, Hôpital Robert Debré, AP-HOP Paris, 48 boulevard Serurier, 75019 Paris, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
The central neurotoxicity of cytotoxic drugs depends on their ability to cross the blood-brain barrier (BBB). The drugs with the highest neurotoxicity are therefore those that cross the BBB most easily: alkylating agents (metabolites of cyclophosphamide and ifosfamide, thiotepa and high-dose melphalan), busulfan, platinum derivatives, aracytine and methotrexate. Apart from aracytine-induced cerebellar toxicity, the clinical signs suggestive of chemotherapy neurotoxicity are relatively nonspecific: altered level of consciousness, seizures, behavioural disorders and motor deficits. Nevertheless, a good knowledge of the various neurological syndromes likely to occur can allow them to be attributed to a drug-induced cause. However, as patients may be receiving several potentially neurotoxic treatments (chemotherapy, concomitant drugs, neurosurgery, radiotherapy), it is difficult to formally confirm the responsibility of the drug, which should only be considered after confirming the absence of radiological and metabolic abnormalities. A specific antagonist treatment can be administered in rare cases (ifosfamide-induced encephalopathy).
Collapse
Affiliation(s)
- D Orbach
- Département de pédiatrie, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | | | | |
Collapse
|
47
|
Bellaton E, Bertozzi AI, Behar C, Chastagner P, Brisse H, Sainte-Rose C, Doz F, Desjardins L. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol 2003; 87:327-9. [PMID: 12598448 PMCID: PMC1771557 DOI: 10.1136/bjo.87.3.327] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIM The role of neoadjuvant chemotherapy was studied when first line enucleation cannot be safely performed in unilateral extensive retinoblastoma (major buphthalmia or radiologically detectable optic nerve involvement). METHODS Six patients, referred for unilateral retinoblastoma, presented with major buphthalmia (two) or optic nerve invasion (four): they were treated by neoadjuvant chemotherapy using etoposide and carboplatin. RESULTS Good tumour response was observed in the two patients with buphthalmia and in three of four cases with optic nerve involvement. Meningeal progressive disease was observed in the last patient. The five patients without disease progression were then operated on: anterior enucleation in the patients with buphthalmia and enucleation via a double neurosurgical and ophthalmological approach with prechiasmatic optic nerve section in the other three cases. Postoperative chemotherapy was performed in these five patients. Local radiotherapy to the chiasmatic region and posterior part of the optic canal was necessary in only one patient. The non-operated patient died with disease progression 6 months after the diagnosis. The other five patients are alive with a follow up of 12, 15, 21, 36, and 40 months after stopping treatment. CONCLUSION Neoadjuvant chemotherapy can be useful in extensive unilateral retinoblastoma with buphthalmia and/or radiological optic nerve invasion at diagnosis.
Collapse
|
48
|
Sauvat F, Sarnacki S, Brisse H, Medioni J, Rubie H, Aigrain Y, Gauthier F, Audry G, Helardot P, Landais P, Michon J, Hartmann O, Nihoul-Fékété C. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 2002; 94:2474-80. [PMID: 12015773 DOI: 10.1002/cncr.10502] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND The growing use of abdominal ultrasonography during pregnancy and in the postnatal period is leading to the discovery of an increasing number of suprarenal masses. The optimal diagnosis and treatment of these masses has not yet been determined. METHODS The authors reviewed the files of patients with suprarenal masses detected prenatally or during the first 3 months of life, between 1986 and 1999, in the pediatric surgery and oncology departments of Paris hospitals. RESULTS Thirty masses were detected prenatally and 23 postnatally. In the latter group of patients, the diagnosis was based on ultrasound in 8 cases and on the palpation of a mass in 15 cases, 13 of which were neuroblastoma. At birth, the masses were cystic in 19 cases, solid in 17, and mixed in 13. Sensitivities of methyliodobenzylguanidine and urinary catecholamine assay were 70% and 52% respectively. Surgery was performed in 38 cases with a median age of 42 days. Histologic analysis showed 31 neuroblastomas, 1 adrenal hemorrhage, 2 necrotic masses, 1 bronchogenic cyst, and 3 sequestrations. All the patients were alive and disease free, at a follow-up ranging from 3 months to 13 years. CONCLUSIONS In this series, 58% of the suprarenal masses diagnosed perinatally were localized neuroblastoma with a favorable outcome. All other cases either regressed spontaneously or turned out to be benign lesion. Thus, the management of these masses must strike a compromise between aggressive treatment and a wait-and-see attitude. This requires appropriate initial assessment and a close follow-up in a specialized center.
Collapse
Affiliation(s)
- Frederique Sauvat
- Department of Pediatric Surgery, Hôpital Necker Enfants-Malades, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Chateil J, Brisse H, Dacher J. [Ultrasound in pediatric urology]. J Radiol 2001; 82:781-800; discussion 801-2. [PMID: 11443296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
UNLABELLED GENERAL OBJECTIVE: To review technical considerations, indications, findings and limitations of ultrasound and Doppler in pediatric urology. EDUCATIONAL OBJECTIVES This course aims to help the reader improve his/her own technical skills and knowledge of ultrasound findings as well as their significance in pediatric urology. The most common causes of misinterpretation and limitations are reviewed. The scope of the article is limited to common diseases: infection, urinary tract malformation, trauma and tumor. Because ultrasound cannot be separated from other imaging modalities, the indications for each of these imaging modalities are provided in relevant sections.
Collapse
Affiliation(s)
- J Chateil
- Radiologie Pédiatrique, Hôpital Pellegrin, Place Amélie Raba Léon, 33076 Bordeaux
| | | | | |
Collapse
|
50
|
Brisse H, Edeline V, Michon J, Couanet D, Zucker J, Neuenschwander S. [Current strategy for the imaging of neuroblastoma]. J Radiol 2001; 82:447-54. [PMID: 11353899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/16/2023]
Abstract
Advances in the management of neuroblastoma lead radiologists and nuclear medicine specialists to optimize their procedures in order to propose a rational use of their techniques, adjusted to the various clinical presentations and to therapeutic management. The aim of this paper is to assess the imaging procedures for the diagnosis and follow-up of neuroblastoma in children according to current therapeutic European protocols. An imaging strategy at diagnosis is first proposed: optimal assessment of local extension of the primary tumour is made with MRI, or spiral-CT when MRI is not available, for all locations except for abdominal tumours for which CT remains the best imaging modality. Metastatic extension is assessed with mIBG scan and liver sonography. Indications for bone metastasis evaluation with either radiological or radionuclide techniques are detailed. Imaging follow-up during treatment for metastatic or unresectable tumours is described. A check-list of radiological main points to be evaluated before surgery is proposed for localized neuroblastoma. The imaging strategy for the diagnosis of "occult" neuroblastoma is considered. Finally, we explain the management of neuroblastoma detected during the prenatal or neonatal period.
Collapse
Affiliation(s)
- H Brisse
- Service de Radiodiagnostic, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | | | | | | | | | | |
Collapse
|